Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC-ESTRO OligoCare consortium.

Stereotactic body radiotherapy (SBRT) for patients with metastatic cancer, especially when characterised by a low tumour burden (ie, oligometastatic disease), receiving targeted therapy or immunotherapy has become a frequently practised and guideline-supported treatment strategy. Despite the increasing use in routine clinical practice, there is little information on the safety of combining SBRT with modern targeted therapy or immunotherapy and a paucity of high-level evidence to guide clinical management. A systematic literature review was performed to identify the toxicity profiles of combined metastases-directed SBRT and targeted therapy or immunotherapy. These results served as the basis for an international Delphi consensus process among 28 interdisciplinary experts who are members of the European Society for Radiotherapy and Oncology (ESTRO) and European Organisation for Research and Treatment of Cancer (EORTC) OligoCare consortium. Consensus was sought about risk mitigation strategies of metastases-directed SBRT combined with targeted therapy or immunotherapy; a potential need for and length of interruption to targeted therapy or immunotherapy around SBRT delivery; and potential adaptations of radiation dose and fractionation. Results of this systematic review and consensus process compile the best available evidence for safe combination of metastases-directed SBRT and targeted therapy or immunotherapy for patients with metastatic or oligometastatic cancer and aim to guide today's clinical practice and the design of future clinical trials.

Informations de copyright

Copyright © 2023 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests FA declares payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Varian, Elekta, Brainlabs, outside of this Policy Review. CBe declares payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Novartis. CBe also declares support for attending meetings and travel from Pfizer and Eli Lilly, unrelated to this Policy Review. CBi declares payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from SPCC congress, unrelated to this Policy Review. BdB declares payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Debiopharma, Ipsen, and Astellas; support for attending meetings and travel from Debiopharma and Micropos medical; and leadership or fiduciary role in the board, society, committee, or advocacy group of ESTRO, SAKK, and SASRO, unrelated to this Policy Review. BAJ-F declares grants or contracts from Italian Association for Cancer Research, FIEO-CCM and FUV, Accuray, and IBA Dosimetry; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Janssen, Bayer, Roche, Astellas, Ipsen, and Accuray; and participation on a data safety monitoring board or advisory board for Bayer, unrelated to this Policy Review. XG declares a grant from Varian paid to their institution; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events for Congress Care and Sanofi; and a leadership or fiduciary role in the board, society, committee, or advocacy group for RIZIV–INAMI and FANC–AFCN. YL declares grants or contracts from ImmunoSABR, EU Project, and HERO–VBHC; consulting fees paid to the institution by AstraZeneca; and a leadership or fiduciary role in the board, society, committee, or advocacy group of ESTRO, Belgian College of Oncology, and EORTC–ESTRO Radiation Infrastructure for Europe project, unrelated to this Policy Review. PO declares grants or contracts from Varian and Bayer; consulting fees from Bayer, AAA, Curium, Janssen, Telix, MSD, and Ferring; and support for attending meetings and travel from Ferring, unrelated to this Policy Review. SP declares personal fees from Amgen, AstraZeneca, Bayer, Beigene, Blueprint, BMS, Boehringer Ingelheim, Daiichi Sankyo, Guardant Health, Incyte, Janssen, Eli Lilly, Merck Serono, MSD, Novartis, Roche, Takeda, Pfizer, Seattle Genetics, Turning Point Therapeutics, and EQRx; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational event from AstraZeneca, Bayer, Guardant Health, Janssen, Merck Sereno, Roche, Takeda, and Pfizer; payment for expert testimony from Roche and Merck Sereno; support for attending meetings and travel from Janssen and Roche; participation on a data safety monitoring board or advisory board for Amgen, AstraZeneca, Bayer, Beigene, Blueprint, BMS, Boehringer Ingelheim, Daiichi Sankyo, Guardant Health, Incyte, Janssen, Eli Lilly, Merck Serono, MSD, Novartis, Roche, Takeda, Pfizer, and Seattle Genetics; and leadership or fiduciary role in the board, society, committee, or advocacy group of British Thoracic Oncology Group, ALK Positive UK, Lung Cancer Europe, Ruth Strauss Foundation, Mesothelioma Applied Research Foundation, and ETOP–IBCSG Partners Foundation Board, unrelated to this Policy Review. SR declares payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from MSD Italia, Genetec, and Istituto Gentili Amgen; and participation on a data safety monitoring board or advisory board for Roche and AstraZeneca, unrelated to this Policy Review. UR declares payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Elekta and Accuray, unrelated to this Policy Review. MS declares payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Janssen, Roche, and Merck; participation on a data safety monitoring board or advisory board for Janssen, Ipsen, and Merck; and a leadership or fiduciary role in the board, society, committee, or advocacy group for ESMO, unrelated to this Policy Review. TZ declares grants or contracts from Varian Medical Systems and Debiopharm; consulting fees from Janssen and Astellas; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Janssen, Astellas, Debiopharm, Bayer, and Ferring; support for attending meetings and travel from Debiopharm; and participation on a data safety monitoring board or advisory board for SAKK scientific board and GFRU, unrelated to this Policy Review. All other authors report no conflict of interest.